Company profile
Annovis Bio, Inc.
NYSE:ANVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Buntanetap | phase3 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05686044 | phase2_3 | completed | 2023-04-01 | 2024-02-13 | Annovis Bio Inc. | A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
| NCT06709014 | phase3 | active_not_recruiting | 2025-02-04 | 2027-12-01 | Annovis Bio Inc. | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD |
| NCT05357989 | phase3 | completed | 2022-08-03 | 2023-12-04 | Annovis Bio Inc. | A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
| NCT07284784 | phase2_3 | recruiting | 2026-01-09 | 2029-09-01 | Annovis Bio Inc. | A Study of Buntanetap in Participants With PD |
| NCT07757204 | phase2_3 | not_yet_recruiting | 2026-09-21 | 2030-02-21 | Annovis Bio Inc. | An Open-label Long-term Safety Study of Buntanetap in Participants With AD |
FDA applications (0)
No records yet.